Slide 1: eur
eur
Slide 2: Agenda
‘Stide'Z hairman’s address Ordinary business and acceptance of Remuneration Report Commendation to Ko Koike for his dedication to the Board and his valuable years of service. Special thank you from the Chairman, Board and staff Meeting closes
Slide 3: mii
mii i TA Slides ‘Pet
Slide 4: Key strategies, key milestones, the road forward
ii i Ng INI heen ) Ke Key strategies. Key milestones. The road forward. ‘Sides
Slide 5: Year in review
‘Stide es d revenues of $38m compared to last year’s $34m. L acquired and included in results for 10 months. nderlying sleep, EEG and Neuroscan businesses performed below xpectations. ;hanges have occurred and are showing early signs of working, being he employment of: VP Sales, America’s VP Marketi
Slide 6: Market leader positions
1,400 beds of sleep diagnostics installed in the USA. 1 market leader in Brain research in the USA. No 1 market leader in sleep diagnostics in Japan. 1 market leader position in sleep diagnostics (70% share) in ustralia. No. 1 market leader position in clinical EEG (40% share) in Australia. No. 1 ma
Slide 7: Proprietary technology in high growth markets
‘Stide7 oprietary technology in three high growth emerging markets. xisting business, with proven technologies and products. Existing business with significant proven organic growth Significant expansion opportunities into: e USA « Europe e Asia The Company has increased its sales more than 4-fold f
Slide 8: Sleep disorders, neurophysiology and blood flow markets
Sleep disorders » 80% sleep diagnostic market share in Australia * 12% sleep diagnostic market share in the USA and growing » Major market share in Japan * Emerging market share in Europe ° Neurophysiology 70% brain research market share in USA » 60% market share in clinical EEG in Australia » Growi
Slide 9: Trading since 1987
mpumedics has been trading since 1987. ~Compumedics has sold direct in the USA since 2002, with significant opportunity for future growth still to be realised. _USA growth complimented by Asian and European opportunities, _ particularly China, Germany and France. | Strong revenue growth already achi
Slide 10: Record of achievement and awards
@-; 2005 « 2005 Hide 40 cr ee i wong * Sige wren 7 5) AWARDS 2004 Deloitte Technology Fast 50 2003 Frost & Sullivan Award for Market Expansion 2003 David Burton-Centenary Medal edics has an impressive 2002 David Burton-Clunies Ross National Science and ord of achievement : Technology Award : 2001 Go
Slide 11: Diagnostics
ats vr cd Nha tke nrg ted 21 Cope 8 aby 1S peat pve. Cae Pas deanietickes kre si Se, gs ae eg le Se ovata ates Cunt REPS seh Sarin BI: sBnS oh Des AS i UMN na Readies Ae pus 1805 rhage sIa ka aap achat SHER ner nebbravts art pinnae tees Labtery a tieks Prieta: aE ocanbraes parce vob exe ier ph aapen
Slide 12: DWL business is up and running
DWL business is up and running. omplementary brain function technology based on Doppler Sonography. Building our base in Europe. 60% market share in Germany. Good opportunity to globalise technology. Hide 42
Slide 13: Financial results
ani MN Hide 43 SIS Operating Revenue 32.1 34.0 38.2 EBITDA 1.9 2.9 (2.6) EBIT (18.8) 2.4 (3.9) Profit after Tax (18.6) 2.4 (3.9) Gross Margin 57% 59% 53% epronon [ex | om | arm Profit after tax/Op. nla 7%, (40.2) Revenue
Slide 14: Balance sheet
Total c iti : ON CURRENT LIABILITIES Hike 44
Slide 15: Costs, margins and working capital
Hide AS 's under focus Investments in new sales and marketing resources have been made so the company will continue to be vigilant with monitoring its expenses whilst these incremental expenses bear fruit through greater sales. rgins | June 04 - 57%, June 05 — 53%. ' Arenewed focus on margins is cur
Slide 16: Bank covenants and cost reductions
Hide 4 ue to the end of September sales not being as strong as anticipated n the company’s financial modeling, the company is not compliant with one of several covenants in its bank facility as at the end of the September quarter. The bank has expressed ongoing support for the company and its strate
Slide 17: Hide
‘00 ‘07 Hide 47
Slide 18: International expansion
mii i rnational expansion | to cc 5 2001 2002 2003 2004 ZAsia 0 Europe O Australia O USA Hide 48
Slide 19: Global research and sleep diagnostics market
Hide 49 Global By Research market AS $7 OM p bal Bleep Didgnas Woariket
Slide 20: Strategy
iii oe en "Strate i zi 0 a /ith Compumedics’ core strategic edge being Sleep di Leveraging this technology into related fields including Hide 20
Slide 21: Outlook for year ending June 2006
ynues expected to continue growing beyond million for year ended June 30, 2006. rgins have improved since June 2005. Earnings to be restored during the financial year. esearch and development expenditure expected to be between 16% and 18% of revenue, for year ended June 0, 2006. The cost efficiency
Slide 22: Medical innovation breakthroughs
iit Medical Innovation breakthroughs now in patent and clinical proof of concept phase. Shida 22 6
Slide 23: Q1 update
TINA Q1 er results were strong in Asia, Australia and Europe and erging in the USA, this held Q1 numbers back. Clear focus on costs and profitability, while sustaining Hide 23
Slide 24: Director resignation, re-election and remuneration vote
o Koike has resigned as a Director for health ons. Alan Anderson who retires by rotation offers himself re-election to the position of Non-Executive Director. Non binding vote on remuneration report. Hide 24
Slide 25: Thank You